Calcium-Sensing Receptor Antagonists I - CAS 478963-79-0
Catalog number:
478963-79-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C23H24N2O2
Molecular Weight:
360.45
COA:
Inquire
Targets:
CaSR
Description:
Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
2(1H)-Quinazolinone, 1-(1-methylethyl)-4-[4-(1-methylethyl)phenyl]-6-(2-propyn-1-yloxy)-
MSDS:
Inquire
1.Secretory diarrhoea: mechanisms and emerging therapies.
Thiagarajah JR1, Donowitz M2, Verkman AS3. Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):446-57. doi: 10.1038/nrgastro.2015.111. Epub 2015 Jun 30.
Diarrhoeal disease remains a major health burden worldwide. Secretory diarrhoeas are caused by certain bacterial and viral infections, inflammatory processes, drugs and genetic disorders. Fluid secretion across the intestinal epithelium in secretory diarrhoeas involves multiple ion and solute transporters, as well as activation of cyclic nucleotide and Ca(2+) signalling pathways. In many secretory diarrhoeas, activation of Cl(-) channels in the apical membrane of enterocytes, including the cystic fibrosis transmembrane conductance regulator and Ca(2+)-activated Cl(-) channels, increases fluid secretion, while inhibition of Na(+) transport reduces fluid absorption. Current treatment of diarrhoea includes replacement of fluid and electrolyte losses using oral rehydration solutions, and drugs targeting intestinal motility or fluid secretion. Therapeutics in the development pipeline target intestinal ion channels and transporters, regulatory proteins and cell surface receptors.
2.[Bone and Nutrition. A prospect of calcium sensing receptor].
Endo I1. Clin Calcium. 2015 Jul;25(7):1029-36. doi: CliCa150710291036.
Following the discovery of the calcium-sensing receptor (CaSR) in 1993, its pivotal role in disorders of calcium homeostasis was demonstrated. Compelling evidence suggests that the CaSR plays multiple roles extending well beyond not only regulating the level of extracellular Ca(2+), but also controlling diverse and crucial roles in human physiology and pathophysiology. This review covers current knowledge of the role of the CaSR in disorders of calcium homeostasis (familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, autosomal dominant hypocalcemia, primary and secondary hyperparathyroidism, hypercalcemia of malignancy) as well as unrelated diseases such as breast and colorectal cancer, Alzheimer's disease and pancreatitis. In addition, it examines the use or potential use of CaSR agonists or antagonists in the management of disorders as diverse as hyperparathyroidism and Alzheimer's disease.
3.Design and synthesis of calindol derivatives as potent and selective calcium sensing receptor agonists.
Kiefer L1, Beaumard F1, Gorojankina T2, Faure H2, Ruat M2, Dodd RH3. Bioorg Med Chem. 2016 Feb 15;24(4):554-69. doi: 10.1016/j.bmc.2015.12.019. Epub 2015 Dec 12.
We report the first comprehensive structure-activity study of calindol (4, (R)-N-[(1H-indol-2-yl)methyl]-1-(1-naphthyl)ethanamine), a positive allosteric modulator, or calcimimetic, of the calcium sensing receptor (CaSR). While replacement of the naphthyl moiety of calindol by other aromatic groups (phenyl, biphenyl) was largely detrimental to calcimimetic activity, incorporation of substituents on the 4, 5 or 7 position of the indole portion of calindol was found to provide either equipotent derivatives compared to calindol (e.g., 4-phenyl, 4-hydroxy, 5-hydroxycalindol 44, 52, 53) or, in the case of 7-nitrocalindol (51), a 6-fold more active calcimimetic displaying an EC50 of 20nM. Unlike calindol, the more active CaSR calcimimetics were shown not to act as antagonists of the closely related GPRC6A receptor, suggesting a more selective profile for these new analogues.
4.Borneol inhibits TRPA1, a proinflammatory and noxious pain-sensing cation channel.
Sherkheli MA1, Schreiner B2, Haq R1, Werner M2, Hatt H2. Pak J Pharm Sci. 2015 Jul;28(4):1357-63.
Borneol, a natural product isolated from several species of Artemisia, Blumea and Kaempferia, has a widespread use in traditional medicine. TRP ion channels are a class of nonselective cation channel proteins involved in a variety of physiological and pathological processes in mammals. TRPA1, a member of TRP family of cation channels, is involved in plethora of processes including noxious-cold, noxious-pain sensations, inflammation and the detection of irritant chemicals. Borneol is chemically related to camphor (a known inhibitor of TRPA1 ion channels); therefore, it is beneficial to investigate the effects of borneol on TRPA1. In the present investigation it was found that borneol inhibits TRPA1 mediated cationic currents in low millimolar range (IC50 0.3mM) in heterologous expression systems like Xenopus oocytes and in neurons cultured from trigeminal ganglia. Effects of nicotine, a known chemical irritant and agonist of TRPA1 are also inhibited by borneol in both systems.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CaSR Products


ENCALERET SULFATE
(CAS: 1214922-52-7)

This active molecular is an CaSR (calcium-sensing receptor antagonist) under the developmet of Tobacco and Merck & Co. Calcium-sensing receptor is a member of t...

CAS 135459-87-9 Strontium Ranelate

Strontium Ranelate
(CAS: 135459-87-9)

Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while ac...

CAS 284035-33-2 NPS-2143

NPS-2143
(CAS: 284035-33-2)

NPS-2143(SB 262470A ) is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroi...

CAS 324523-20-8 NPS-2143 hydrochloride

NPS-2143 hydrochloride
(CAS: 324523-20-8)

NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyro...

CAS 226256-56-0 Cinacalcet

Cinacalcet
(CAS: 226256-56-0)

Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patie...

CAS 364782-34-3 Cinacalcet hydrochloride

Cinacalcet hydrochloride
(CAS: 364782-34-3)

Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.

Etelcalcetide hydrochloride
(CAS: 1334237-71-6)

Etelcalcetide is a Calcium-sensing receptor agonist as a D-amino peptide calcimimetic for the treatment of secondary hyperparathyroidism. It can bind to and act...

CAS 753449-67-1 Ronacaleret

Ronacaleret
(CAS: 753449-67-1)

Ronacaleret is a calcium-sensing receptor (CaSR) antagonist under the development of GlaxoSmithKline. It is potential for therapeutic utility in the stimulation...

Evocalcet
(CAS: 870964-67-3)

Evocalcet is a calcium-sensing receptor agonist under the development of Kyowa Hakko Kirin. Phase III clinical trials for Secondary hyperparathyroidism are on-g...

CAS 787583-71-5 Encaleret

Encaleret
(CAS: 787583-71-5)

Encaleret is a calcium-sensing receptor (CaSR) antagonist. But in Oct 2011, Phase-II for Osteoporosis in USA was discontinued.

CAS 478963-79-0 Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
(CAS: 478963-79-0)

Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.

Chemical Structure

CAS 478963-79-0 Calcium-Sensing Receptor Antagonists I

Quick Inquiry

Verification code

Featured Items